ILMN — Deep Dive

Deep Dive Ticker Tape
10 min read

ILMN — Deep Dive

1 tickers referenced · published Aug 12, 2026

Article published Aug 12, 2026. Prices below use latest available snapshots.

ILMN $193.14 +3.5% 30d

Thesis: Durable-grower engine real (100% beat rate, margin expansion, self-funding FCF) but the tape re-rated most of it after a +92.6% year - the graded record says buy the in-trend pullback, never the fresh-high chase; today's print sits on the 20-day, the shape that won

The Story Right Now

The desk has two graded shadow calls on this name three weeks apart, and they disagree sharply about where the edge in Illumina actually lives. The July 16 buy came on a minor pullback near highs — confirmed uptrend, golden cross, 3.3% off the high — and returned +3.47% over the next week against a −1.67% SPY, a +5.14-point excess win. The July 31 buy came at a fresh 52-week high after a +5.7% weekly breakout — and lost −8.36% over the next week against a +3.51% SPY, an −11.87-point excess miss, as the stock rolled over hard through the first week of August. Same stock, same uptrend, three weeks apart: one entry got paid, the other got run over. That is the empirical case for "intact, but priced" as a real distinction rather than a hedge — the trend has legs, but where you enter inside it is the difference between a win and a double-digit relative loss.

On fundamentals, the growth is not just sentiment. Illumina's quarter ended June 28, 2026 (filed July 31, 2026) posted $1.159 billion of revenue, a 66.4% gross margin and 21.1% operating margin — both up from the same quarter a year earlier (65.6% gross margin, 20.2% operating margin) — and $207 million of net income. Fiscal 2025 (year ended December 28, 2025) revenue was $4.34 billion with $807.0 million of operating income, $850.0 million of net income, $1.08 billion of operating cash flow against $148.0 million of capex, all GAAP per SEC XBRL. The trailing 100% earnings-beat rate is not a one-quarter fluke on this record.

But the growth rate is where the crack under "priced" shows up. The revenue-growth signal reads bearish on a sequential basis: the latest quarter-over-quarter growth rate fell 12.79 percentage points versus the prior quarter (latest QoQ −5.87% against a prior +6.92%), even though the year-over-year comparison for the same quarter stayed positive at +4.8%–9.4% depending on the window. A business decelerating sequentially, trading up 92.63% over the past year and 32.35% over three months, is a stock where the multiple — not the quarter's growth — has done most of the recent work. Layer on net insider selling (4 buys versus 14 sells, net value −$303.1 million) and a fresh trip to the capital markets — a 424B2 prospectus supplement and an accompanying free-writing prospectus, both filed August 10 — while the stock still sits within single digits of its 52-week high, and the pattern reads like a company using strength to raise capital, not one about to guide dramatically higher. The filings on record don't specify the instrument or its size; a 424B2/FWP pair is typically used for a securities offering (commonly debt) off an existing shelf registration, but that's as far as the record supports.

On GRAIL: nothing in the balance sheet or income statement carries an explicit discontinued-operations or divestiture line, and the recent news scan shows GRAIL trading as its own listed company (GRAL) rather than as part of Illumina's results — consistent with a genuinely GRAIL-free consolidated P&L, but that read is an inference from steady quarterly profitability and the absence of a drag line, not a stated fact in the data on hand. Net: the durable-grower case is real — beats, margin expansion, self-funding cash flow, historically near-zero funded debt — and the "priced" case is also real — sequential deceleration, insiders selling into strength, and a stock up 92.6% over the year now working through a pullback. The desk's own record says buy the pullback inside the trend, don't chase the new high; the tape sitting on its 20-day average after a 5% weekly drawdown looks like the July 16 setup, not the July 31 one.

Setup

Current price $192.84 (August 11 close), RSI 52.2 — cooled off from overbought back to neutral — in a strong-up trend, regime uptrend, golden cross intact. Weekly: −5.01% (7d). Monthly: +1.47% (30d). Quarterly: +32.35% (3m). Trailing year: +92.63% (1y). The stock is −6.84% off its 52-week high, and that high — $207.00 — was printed inside the last 30 trading days (July 13–August 11 window), alongside a 30-day low of $178.88. Price is running about 0.5% below its 20-day moving average, i.e., the pullback has brought the stock right back to short-term trend support without breaking the broader uptrend structure. (All figures as of the August 11 close.)

  • Entry zone: roughly $188–$194 — the stock is already at trend support after a −5.01% week; structurally the same "minor pullback near highs" setup as the July 16 entry that won, not the fresh-high breakout that lost on July 31.
  • Stop: below $178.88, the 30-day low. A break of that level would violate the pullback-inside-an-uptrend structure this setup depends on and would call the strong-up/golden-cross read into question.
  • Target: first objective is a retest of $207.00, the 30-day/52-week high; no fixed cap beyond that under trend-hold doctrine — a 15% give-back off peak governs the trailing exit after a +30% gain.

Bull Case

  1. Consistent earnings execution. A 100% trailing earnings-beat rate — management has repeatedly beaten its own guidance, not just met it.
  2. Margin expansion, not just revenue growth. Gross margin 66.4% versus 65.6% a year earlier; operating margin 21.1% versus 20.2% a year earlier, same-quarter comparison.
  3. Self-funding cash generation. Fiscal 2025 operating cash flow of $1.08 billion against $148.0 million of capex — free cash flow around $0.93 billion (FY2025, GAAP), a roughly 21.4% FCF margin against that year's revenue.
  4. Low historical leverage. Reported debt-to-equity of 0.00 on funded debt — Illumina has run essentially debt-free, exactly the balance-sheet flexibility a durable grower is supposed to have (though see the Bear Case on the August 10 filing, and note total liabilities of $3.812B against $2.838B of equity are the broader measure).
  5. Trend structure intact. Regime is still uptrend with a golden cross despite the pullback, and the stock remains up 92.63% over the trailing year — the underlying momentum hasn't broken, it's cooled.

Bear Case

  1. Sequential growth deceleration. QoQ growth rate fell 12.79 percentage points versus the prior quarter (latest QoQ −5.87% versus prior +6.92%) even as YoY growth held positive — the revenue signal reads outright bearish on that basis.
  2. Heavy net insider selling. 4 buys versus 14 sells, net value −$303.1 million — insiders are not buying this strength.
  3. The tape already paid for the good news. +92.63% over one year and +32.35% over three months; the July 31 chase-the-breakout call lost −8.36% (−11.87 points versus SPY) over the following week, direct evidence the market itself punished paying up here.
  4. New capital-markets activity into strength. A 424B2 prospectus supplement and an FWP were both filed August 10, while the stock traded within single digits of its 52-week high — if this converts to a bond offering, it would mark new leverage for a company that has historically run near-debt-free; the filings on record don't disclose the use of proceeds or terms.
  5. External valuation pushback. A Yahoo Finance headline in the news scan flagged Illumina as potentially "19% Overvalued Following Its Q2 Beat" (August 8) alongside a companion piece questioning whether the stock can "Hold Its Price As Cash Flow And Earnings" hold up — reported as headlines from the scan, not independently verified analysis.
  6. Net income didn't track operating income YoY. Same-quarter comparison: operating income rose to $245 million from $214 million a year earlier, but net income fell to $207 million from $235 million over the same window. The fundamentals data doesn't carry a below-the-line detail (other income/expense, tax reconciliation) to explain the gap — cause unknown from the data on hand.

Catalysts

  • Next quarterly print. No specific date is on record in the sources reviewed; the 100% beat streak raises the bar each time.
  • Resolution/pricing of the August 10 filing. The 424B2 and FWP are on record as filed; terms, size, and use of proceeds are not yet disclosed in the data reviewed.
  • The August 7 8-K. Present in the filings list with no content summary on hand — a disclosure event to watch, not yet characterized.
  • Continued insider Form 4 activity. Multiple Form 4s filed August 3 and August 6, plus a Form 144 August 4 and a Form 3 August 11 (a new filer) — worth tracking for whether the net-sell pattern continues.
  • GRAIL-adjacent sentiment. GRAIL trades separately now (GRAL); an August 1 Motley Fool piece on GRAIL's own valuation is in the news scan and could still color sentiment around the Illumina name given the shared history, even though the two are now distinct companies.

Risks

  • Valuation/multiple-compression risk. After a +92.63% one-year move, any deceleration confirmation at the next print is a plausible trigger for multiple compression, not just a pause.
  • Growth-deceleration risk. The QoQ deceleration is the single largest crack in the "durable grower" framing right now.
  • Leverage/dilution risk from the new filing. Until the 424B2's terms are disclosed, the risk of new interest expense (if debt) or share dilution (if equity-linked) can't be sized from the record.
  • Selling-into-strength risk. Net insider selling of this magnitude alongside a capital-markets filing is a pattern worth discounting management's own confidence in the stock at current levels.
  • Stale risk-factor visibility. The only 10-K business/risk-factor text available in this corpus is dated to a filing from 2016 — a decade old and pre-dating even the GRAIL divestiture story fully playing out. It cannot be used to characterize Illumina's current competitive or regulatory risk profile; that gap is a real blind spot in this dive, not a stated current risk.

Financials

All figures GAAP, per SEC XBRL (EDGAR) and Massive/Polygon fundamentals; quarters are labeled by fiscal period-end date (the feed's own fiscal-year/quarter tags are internally inconsistent for the two most recent quarters, so the dates are the authority).

Quarterly trend (revenue / gross profit / operating income / net income / diluted EPS, $ millions except EPS):

Quarter ended Revenue Gross profit Operating income Net income Diluted EPS
2025-03-30 $1,041M $683M $164M $131M $0.82
2025-06-29 $1,059M $695M $214M $235M $1.49
2025-09-28 $1,084M $733M $227M $150M $0.98
2025-12-28 $1,159M $759M $201M $334M $2.16
2026-03-29 $1,091M $721M $209M $134M $0.87
2026-06-28 $1,159M $770M $245M $207M $1.35

Gross margin, latest quarter (2026-06-28) vs. same quarter a year earlier (2025-06-29): 66.4% vs. 65.6%. Operating margin, same comparison: 21.1% vs. 20.2%.

Fiscal 2025 annual (year ended 2025-12-28, GAAP, EDGAR XBRL): Revenue $4.34B; operating income $807.0M; net income $850.0M; diluted EPS $5.45; operating cash flow $1.08B; capex $148.0M. Free cash flow (operating cash flow less capex) for FY2025 is approximately $0.93B, a 21.4% FCF margin against FY2025 revenue.

Balance sheet, most recent quarter (period ended 2026-06-28, filed 2026-07-31): total assets $6.65B; total liabilities $3.812B; total equity $2.838B; total current assets $2.834B; total current liabilities $1.578B; inventories $629M; intangible assets $410M. Debt-to-equity reads 0.00 on funded/interest-bearing debt — total liabilities of $3.812B against $2.838B of equity are the broader measure.

GRAIL divestiture: no discontinued-operations or divestiture line item appears in the income-statement or balance-sheet data reviewed. GRAIL's presence as a separately traded company (GRAL, per the news scan) is consistent with a GRAIL-free consolidated P&L here, but the statements on disk don't explicitly label the effect — this is an inference, not a confirmed fact from the filings reviewed.

Short interest: 8.06 million shares short as of settlement date 2026-07-31, 4.51 days to cover, average daily volume 1.79 million shares — down from 8.75 million shares (settlement 2026-07-15) but up from 7.57 million (settlement 2026-06-30). No extreme positioning either direction.

Filer status: Illumina files as a US 10-K filer (CIK 0001110803). Most recent annual report covers fiscal year ended December 28, 2025, filed February 12, 2026. Most recent quarterly report covers the quarter ended June 28, 2026, filed July 31, 2026. Most recent 8-K on record is dated August 7, 2026.

Cross-References

ILMN carries a market cap of $29.1 billion (Massive company data, August 12) and sits on the desk's focus watchlist. The daily briefs have tracked the name through the pullback: the August 10 brief noted $191.79, +2.0% on the day, RSI 51.3 in a confirmed uptrend, and separately flagged the new $ILMN 424B2 filing among the day's notable SEC filings; the August 11 brief noted $192.84, +0.55%, "a real uptrend 6.84% off its high after a −5.01% week," with a note to watch for the next leg. Two graded shadow calls sit in the decisions ledger on this name: the July 16 endorse (won +5.14 points of excess) and the July 31 breakout chase (lost −11.87 points of excess). The prior dive on this name (June 29) set the original "wants a pullback entry" verdict at much lower levels (entry toward $166); this dive re-derives that structure at the current, higher base.

Sources